Approval · Notice of Compliance 36610 · 2025

PLOSBRIO: Notice of Compliance 36610

Issued December 22, 2025

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 36610
Date: December 22, 2025
Company: Novo Nordisk Canada IncMississauga, Ontario, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Labelling Only
Reason: Administrative – Additional product name

Products in this notice

Brand	DIN	Status today
PLOSBRIO	02564068	Approved
PLOSBRIO	02564084	Approved
PLOSBRIO	02564041	Approved
PLOSBRIO	02564076	Approved

Medicinal ingredients

SEMAGLUTIDE 1.34 MG per ML
SEMAGLUTIDE 2.68 MG per ML
SEMAGLUTIDE 0.68 MG per ML